The economic impact of allergic rhinitis and current guidelines for treatment
Introduction
The National Jewish Health Symposium entitled Rethinking the Treatment of Allergic Rhinitis; the Role of Intranasal Antihistamines: “Me-Too” Drugs or a Novel Class? was held in Denver, Colorado, on October 8, 2009. This article discusses two of the symposium topics: the economic impact of treating allergic rhinitis and the current guideline recommendations for therapy.
Section snippets
Economic impact of allergic rhinitis treatment
The Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 Practice Parameter1 defines rhinitis as “a condition characterized by one or more of the following nasal symptoms: congestion, rhinorrhea (anterior and posterior), sneezing, and itching.” Symptoms of rhinitis may occur only during specific seasons, perennially with or without seasonal exacerbation, or episodically after specific aeroallergen exposures. The severity of allergic rhinitis ranges from mild and intermittent to severe and
Current guideline recommendations for therapy for allergic rhinitis
The National Jewish Health symposium faculty reviewed two current guidelines for allergic rhinitis treatment: (1) The Diagnosis and Management of Rhinitis: An Updated Practice Parameter1 from the US-based task force and (2) Allergic Rhinitis and Its Impact on Asthma (ARIA) 2008 Update12 from the group convened by the World Health Organization.
The ARIA guidelines propose a severity classification that is divided into mild or moderate/severe and also a duration classification of intermittent or
Conclusion
The total direct medical cost of allergic rhinitis is approximately $3.4 billion, with nearly half attributable to prescription medications. Patients do not adhere to their medication regimens because of lack of symptoms, they consider the medications ineffective, they feel the medications lose effectiveness over time, they find the medications inconvenient, they find the medications costly, or they are concerned about safety or adverse effects.22, 23 The National Jewish Health panel presented
Acknowledgments
We thank Meda Pharmaceuticals for providing the funding for this research, National Jewish Health for hosting the panel and coordinating publication efforts, Dr Deborah Wilkerson of OmniaVincit LLC for her assistance in writing this article, and Mary E. King, PhD, for editorial assistance.
References (23)
- et al.
The diagnosis and management of rhinitis: an updated practice parameter
J Allergy Clin Immunol
(2008) - et al.
Allergic rhinitis and its impact on asthma
J Allergy Clin Immunol
(2001) - et al.
American Academy of Otolaryngic Allergy Working Group on Allergic RhinitisKeys to successful management of patients with allergic rhinitis: focus on patient confidence, compliance, and satisfaction
Otolaryngol Head Neck Surg
(2007) - et al.
Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device
Ann Allergy Asthma Immunol
(2010) - et al.
Effect of the addition of montelukast to fluticasone propionate for the treatment of perennial allergic rhinitis
Ann Allergy Asthma Immunol
(2010) - et al.
Burden of allergic rhinitis: results from the Pediatric Allergies in America survey
J Allergy Clin Immunol
(2009) - et al.
Allergic rhinoconjunctivitis: diagnostic and clinical assessment
Rhinology
(1992) American Academy of Allergy, Asthma and Immunology
Allergic Rhinitis: Trends in Use and Expenditures, 2000 to 2005
(2008)- et al.
The cost of treating allergic rhinitis
Curr Allergy Asthma Rep
(2002)
Allergic rhinoconjunctivitis: burden of disease
Allergy Asthma Proc
Cited by (215)
Greenness and its composition and configuration in association with allergic rhinitis in preschool children
2024, Environmental ResearchThe Burden of Asthma and Allergic Rhinitis: Epidemiology and Health Care Costs
2024, Otolaryngologic Clinics of North AmericaSurgical and instrumental options for chronic rhinitis: A systematic review and PRISMA meta-analysis
2023, European Annals of Otorhinolaryngology, Head and Neck DiseasesNasal steroid spray simulations using measured spray characteristics in healthy and rhinitic nasal passages
2023, Journal of Aerosol ScienceComparing The Effects of Botulinum toxin-A and multiple surgical parasympathectomy on treatment of allergic rhinitis
2023, American Journal of Otolaryngology - Head and Neck Medicine and Surgery
Disclosures: Dr Meltzer serves as a consultant to Abbott, Alcon, Amgen, AstraZeneca, Boehringer Ingelheim, Capnia, Genentech, GlaxoSmithKline, Greer, Ista, Johnson & Johnson, MAP Pharmaceuticals, Meda, Merck, Novartis, Sanofi-Aventis, Schering-Plough, Sepracor, Teva, and Wyeth; serves as a speaker to AstraZeneca, Alcon, AstraZeneca, Genentech, GlaxoSmithKline, Meda, Merck, Sanofi-Aventis, Schering-Plough, and Sepracor; and receives grant/research support from Alcon, Amgen, Alexza, Astellas, AstraZeneca, Boehringer Ingelheim, Capnia, Genentech, GlaxoSmithKline, MAP Pharmaceuticals, Meda, Merck, Novartis, Sanofi-Aventis, Schering-Plough, Sepracor, and Teva. Dr Bukstein has served as a speaker/consultant/advisor for Merck, Genentech, Novartis Pharmaceuticals, Schering-Plough, 3M Pharmaceuticals, Abbott Laboratories, Sanofi-Aventis, Astra-Zeneca, Critical Therapeutics, Aerocrine, Teva, and King Pharmaceuticals; has received research support from Merck, Astra-Zeneca, Sanofi-Aventis, and Merck; and has commercial interests with HealthyAirways LLC, Strategic Pharmaceutical Advisors, and the PBL Institute. Dr. Wilkerson has not served as a consultant or speaker for any allergy or asthma pharmaceutical company.
Funding Sources: This consensus panel received a grant from Meda Pharmaceuticals to explore the role of intranasal antihistamines in the treatment of allergic rhinitis.
Requests for reprints should be addressed to: Office of Professional Education, National Jewish Health, 1400 Jackson Street, Denver, CO 80206, USA, Email: [email protected]